CURRENTLast verified 2026-10-07

Good regulatory oversight of clinical trials — Egypt

Country: Egypt
Official organization: Egyptian Drug Authority (EDA)
Category: standards compliance
Product / sector: Biological Products · Pharmaceuticals
Publication / issue date: 2026-07-01
Document version: 05
Official source: Guideline for Good Regulatory Oversight of Clinical Trials by Egyptian Drug Authority

OFFICIAL SOURCE FACTS / REQUIREMENT FRAMEWORK

What you need to know

EDA version 05 outlines clinical-trial regulatory oversight and application steps for investigational medicinal products.
The guideline directs readers to consider it alongside applicable clinical-trial law, executive regulations and relevant GCP guidance.

This summary is not a complete regulatory checklist. Applicability, conditions and exclusions remain governed by the original official document.

Who is affected

Clinical-trial sponsors
CROs
Investigators
Regulatory Affairs teams

PHARMA GATE INTERPRETATION — NOT AN OFFICIAL REQUIREMENT

Pharma Gate Intelligence

Review this source as clinical-trial guidance, not as a substitute for product-registration approval.

Business impact

Regulatory and evidence planning should be coordinated with trial preparation.

RECOMMENDED ACTION — NOT A REGULATORY DETERMINATION

What to check

Applicable trial route and investigational product
Supporting legal and GCP references
Submission and oversight sections

Recommended next step

Use specialist clinical and regulatory review for the proposed study.

Investigational product
Applicable trial route
Evidence planning
Oversight review
Professional support

NEXT STEP

Need help navigating this requirement?

Pharma Gate is not a regulatory authority. Professional providers are independent organizations subject to platform review.

VERIFIED SOURCE GOVERNANCE

Official facts are attributed to issuing authorities. Pharma Gate analysis and recommended actions are clearly separated.

How we verify intelligence

Official facts are attributed to the issuing organization. Pharma Gate interpretation and recommended actions are separate editorial layers, not legal requirements or regulatory approval. Sources are prioritized: national regulators, WHO and recognized intergovernmental bodies, official procurement organizations, then other official governmental or institutional sources.

Publication records retain source title, version, issue date, verification date, country, sector and status. Draft / Public Consultation is distinct from Current. Superseded and Archived records do not represent current requirements. A verification date records the review performed; it is not an assurance of continuous monitoring. Always check the latest official source before acting.